Nicolas Mach

12PUBLICATIONS
66CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

|Jan 06, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.

Hiba Mechahougui, Léna Royston, Catia Vieira Gomes

|Sep 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Dominic Schmid, Bettina Sobottka, Massimiliano Manzo

|Jul 23, 2024
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.

Rémi Vernet, Eugenio Fernandez, Denis Migliorini

|May 03, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas: Looking Forward to What Is Next.

Brian Schulte, Nicolas Mach, Timothée Olivier

|Aug 26, 2023
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients.

Natacha Bordry, Anne-Claire Mamez, Chiara Fedeli

Pageof 2

Frequent Collaborators

4 joint publications

Stefanie Hayoz

3 joint publications

Sacha I Rothschild

2 joint publications

Francesco Bertoni

2 joint publications

Alfredo Addeo